Myriad's (MYGN) EndoPredict Grows Amid Coronavirus Mayhem 2020/05/18 15:55:00 Zacks Investment Research
Within Molecular Diagnostics, Myriad Genetics (MYGN) registers strong sales for EndoPredict, myChoice CDx and BRACAnalysis CDx.
Myriad Genetics (MYGN) Lags Q3 Earnings Estimates, Cancels View 2020/05/06 15:49:00 Zacks Investment Research
Myriad Genetics (MYGN) reports revenue declines in both reporting segments in Q3 resulting from coronavirus-led business disruptions.
Shared-Use Space For Cannabis Manufacturing To Debut In Southern California 2020/04/07 20:26:29 Benzinga Feeds
My Green Network (MyGN) is set to open a membership-based, entrepreneur-focused, collaborative cannabis facility inin Orange County, California this summer. The company promises to provide “a home, a network, compliance and access to cannabis verticals.” Who Is It For? Average cannabis startup costs are getting higher by the minute. MyGN aims to reduce these costs substantially by helping entrepreneurs target six main barriers: Money Compliance Property Time Experience Legal Uncertainty Founded by attorneys Ken Hwang and James Shih, and visionary brand strategist, Maria Cordeiro, MyGN will focus on fostering a … Full story available on Benzinga.com
Myriad Genetics' (MYGN) BRACAnalysis Gets Japan Reimbursement 2020/04/07 13:32:00 Zacks Investment Research
Myriad Genetics (MYGN) launches BRACAnalysis Diagnostic System in Japan, after receiving reimbursement for the system, which will enable easier identification of HBOC patients.
Myriad Grows Internationally, Hereditary Cancer Revenues Soft 2020/03/19 13:46:00 Zacks Investment Research
Myriad Genetics (MYGN) registers soft Hereditary Cancer, GeneSight, Vectra as well as Prenatal revenues in second-quarter fiscal 2020.
Myriad Genetics (MYGN) Misses Q2 Earnings & Revenue Estimates 2020/02/07 14:56:00 Zacks Investment Research
Myriad Genetics (MYGN) reports decline in Hereditary Cancer, GeneSight, Vectra and Prenatal revenues in Q2.
Myriad Genetics Stock Is Tanking After Earnings. The CEO Is Out. 2020/02/07 13:58:00 MarketWatch
The stock was down by nearly one-third in premarket trading as earnings fell short of Wall Street’s expectations. CEO Mark Capone is resigning.
The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns 2020/02/07 12:32:45 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 6) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (NASDAQ: ALEC ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Arvinas Inc (NASDAQ: ARVN ) Ascendis Pharma A/S (NASDAQ: ASND ) Beam Therapeutics Inc (NASDAQ: BEAM ) (IPOed Thursday) ChemoCentryx Inc (NASDAQ: CCXI ) Eli Lilly And Co (NYSE: LLY ) Fulgent Genetics Inc (NASDAQ: FLGT ) Insmed Incorporated (NASDAQ: INSM ) Insulet Corporation (NASDAQ: PODD ) Johnson & Johnson (NYSE: JNJ ) Novartis AG (NYSE: NVS ) PPD Inc (NASDAQ: PPD ) (IPOed Thursday) Principia Biopharma Inc (NASDAQ: PRNB ) Profound Medical Corp (NASDAQ: PROF ) PTC Therapeutics, Inc (NASDAQ: PTCT ) ResMed Inc. (NYSE: RMD ) Revance Therapeutics Inc (NASDAQ: RVNC ) (announced FDA acceptance of BLA for DAXI to treat frown lines) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) Zimmer Biomet Holdings Inc (NYSE: ZBH ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on Feb.
Myriad Genetics (MYGN) Misses Q2 Earnings and Revenue Estimates 2020/02/06 23:15:07 Zacks Investment Research
Myriad (MYGN) delivered earnings and revenue surprises of -25.81% and -6.76%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
$22.5Bn+ Molecular Diagnostics Market Insights, 2025 - Featuring Company Analysis of Roche Diagnostics, Abbott Laboratories, Myriad Genetics, Qiagen, and bioMerieux 2020/01/29 17:00:00 PR Newswire
/PRNewswire/ -- The "Molecular Diagnostics Market Share & Global Forecast, By Application, Technology, End User, Regions, Companies" report has been added to…
Myriad Genetics Is Tumbling After The Wall Street Journal Highlighted the Risks of Acting on Genetic Testing 2019/12/23 19:42:00 Barron's
Over the weekend, Myriad was the subject of a Wall Street Journal report that profiled a woman who had her ovaries and fallopian tubes removed after a genetic test showed a heightened risk of cancer. Years later, the woman learned that an updated interpretation of the lab results showed that the specific mutation may not be linked to an increase in cancer risk.
Myriad Genetics Reports Favorable Study Result on Prequel 2019/12/05 08:24:00 Zacks Investment Research
Myriad Genetics (MYGN) posts breakthrough results on Prequel Prenatal Screen methodology, proving its superiority over traditional methods.
Myriad (MYGN) Up 18.4% Since Last Earnings Report: Can It Continue? 2019/12/04 16:30:50 Zacks Investment Research
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MYRIAD TUESDAY DEADLINE: ROSEN, A GLOBAL LAW FIRM, Reminds Myriad Genetics, Inc. Investors of November 26th Deadline in Securities Class Action 2019/11/26 01:00:00 PR Newswire
NEW YORK, Nov. 25, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Myriad Genetics, Inc. from September 2, 2016 through August 13, 2019, inclusive (the "Class Period") of the important November 26, 2019 lead plaintiff…